Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

January 01, 1998; 50 (1) Correspondence

Intraventricular α-interferon in subacute sclerosing panencephalitis

Carlo Cianchetti, Maria Giovanna Marrosu, Francesco Muntoni, AnnaLisa Fratta, Alessandro Zuddas
First published January 1, 1998, DOI: https://doi.org/10.1212/WNL.50.1.315
Carlo Cianchetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Giovanna Marrosu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Muntoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AnnaLisa Fratta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Zuddas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Intraventricular α-interferon in subacute sclerosing panencephalitis
Carlo Cianchetti, Maria Giovanna Marrosu, Francesco Muntoni, AnnaLisa Fratta, Alessandro Zuddas
Neurology Jan 1998, 50 (1) 315; DOI: 10.1212/WNL.50.1.315

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
60

Share

  • Article
  • Info & Disclosures
Loading

To the Editor: Anlar et al.1 reported the favorable effect of intraventricular (IVC) human α-interferon (IFN) plus isoprinosine in subacute sclerosing panencephalitis (SSPE). Theirα-IFN treatment regimen consisted of a 6-week course, 5-day/week administration, with a total of 30 × 106 U/m2 (5× 106 U/m2 each week); in some cases (not specified how many), the course was repeated at 2- to 6-month intervals, up to 6 times.

We wonder whether better results could be obtained by a more prolonged administration at slightly lower doses, as done by others2,3 and ourselves4

In the eight patients we have treated since 1986, recombinant α-2a IFN (Roferon A, Roche Laboratories, Nutley, NJ) was given in 1 or 2 IVC administrations/week for at least 6 months, or more if no adverse effect occurred. IVC doses ranged from an initial 0.5 × 106 to a maximum of 2.2 × 106 U/m2 twice a week, reduced to once a week after improvement had occurred. Biological activity of α-2a IFN in CSF of our first three patients was found to be present a week after IVC administration (A. Dolei, Inst. Virology, University of Sassari). In all cases, we added oral isoprinosine (Inosiplex, Newport Pharmaceuticals, Newport Beach, CA) 100 mg/kg/day and, on the basis of the report of measles virus RNA in peripheral blood lymphocytes,5 subcutaneousα2-a IFN 1 to 2 × 106 U/m2 twice a week (in the first two patients treated, we performed a dot-blot hybridization of measles virus RNA in peripheral lymphocytes and found its reduction parallel to clinical improvement).4

Our patients began treatment in an early phase of the disease, i.e., stage 1 or 2a or 2b according to Risk and Haddad.6 In the first months, an improvement, sometimes substantial, of the clinical conditions was observed in all the patients. Consistently, measles antibody titers in CSF and blood and oligoclonal bands in CSF were slightly reduced in most cases.

Early interruption of treatment in two patients was followed by a quick clinical deterioration; in one of these patients, reassumption of IVCα-2a IFN led to adverse effects, which again continued to improve after interruption of treatment. Moreover, after 13 months' administration, we observed in two patients a motor deficit at the lower limbs with an electrophysiologic pattern consistent with spinal motor neuron damage.7

On the complex, our eight treated patients have a mean survival of 41 months (range, 12 to 105), underestimated since four are still alive; they maintained satisfactory clinical conditions (autonomously walking and communicating-that is, not beyond stage 2b) for a mean of 30 months (range, 5 to 105), again underestimated values since three patients are still autonomously walking and communicating. Our preceding population of 11 patients (all deceased) treated with only isoprinosine since early stages (1, 2a, 2b) maintained a clinical condition not beyond stage 2b for a mean of 14 months (range, 4 to 36) and had a mean survival of 25 months (range, 4 to 72).

To evaluate the efficacy of a treatment of SSPE, the duration of a somewhat satisfactory quality of life should be considered more relevant than the total survival time: it is well-known that when patients reach a vegetative state they may naturally survive in this condition for many years, probably irrespective of treatment.

Although it is difficult to compare different case series, we did not evidentiate relevant differences between our results and those obtained by Anlar et al.1 in the 10 of 22 patients treated when still in stage 1 to 2b. However, our experience of deterioration in a few patients after IVC α-IFN withdrawal as well as the improvement with its reassumption suggest the usefulness of a prolonged treatment regimen. This is also suggested by the experience of α-IFN treatment for hepatitis B and C. Speculatively, since α-IFN appears to slow, or temporarily block, proliferation and diffusion of SSPE virus in the central nervous system without eradicating the infection, it seems more appropriate to continue it for as long as possible.

References

  1. 1.↵
    Anlar B, Yalaz K, Oktem F, Kose G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular α-interferon. Neurology 1997;48:526-528.
    OpenUrl
  2. 2.↵
    Panitch HS, Gomez-Plascencia J, Norris FH, Cantell K, Smith RA. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology 1986;36:562-566.
    OpenUrl
  3. 3.
    Gascon G, Yamani S, Crowell J, et al. Combined oral isoprinosine-intraventricular α-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.
    OpenUrlPubMed
  4. 4.↵
    Cianchetti C, Muntoni F, Fratta AL, Marrosu MG. Immunological parameters in subacute sclerosing panencephalitis and the effect of intraventricular interferon. In: Marrosu MG, Cianchetti C, Tavolato B, eds. Trends in Neuroimmunology. New York: Plenum Press, 1990:127-134.
  5. 5.↵
    Fournier JG, Tardieu M, Lebon P, et al. Detection of measles virus RNA in lymphocytes from peripheral blood and brain perivascular infiltrates of patients with subacute sclerosing panencephalitis. N Engl J Med 1985;313:910-915.
    OpenUrl
  6. 6.↵
    Risk WS, Haddad FS. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch Neurol 1979;36:610-614.
    OpenUrl
  7. 7.↵
    Cianchetti C, Fratta AL, Muntoni F, Marrosu G, Marrosu MG. Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis. Ital J Neurol Sci 1994;15:153-155.
    OpenUrlPubMed
  8. 8.
    Anlar B. Subacute sclerosing panencephalitis: diagnosis and drug treatment options. CNS Drugs 1997;7:111-120.
    OpenUrlPubMed
  9. 9.
    Yalaz K, Anlar B, Öktem F, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.
    OpenUrlPubMed
View Abstract

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • References
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise